Date of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster
Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemo-immunotherapy. The CELMoD agents, exemplified by GOLCA, demonstrate potent capabilities in degrading target proteins Ikaros/Aiolos, leading to a multifaceted impact characterized by antiproliferative, apoptotic, and immunomodulatory activities. As per the results presented at the ASH 2023 conference, there were 71 patien...
